50 related articles for article (PubMed ID: 9695747)
1. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients.
Wong PY; Staren ED; Tereshkova N; Braun DP
J Surg Res; 1998 Apr; 76(1):95-103. PubMed ID: 9695747
[TBL] [Abstract][Full Text] [Related]
2. Natural cytotoxicity of lymphocytes from lymph nodes draining breast carcinoma and its augmentation by interferon and OK432.
Yanagawa E; Uchida A; Micksche M
Cancer Immunol Immunother; 1984; 17(1):1-6. PubMed ID: 6563940
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the immune reactivity of infiltrating and peripheral lymphocytes from patients with renal cell carcinoma by measuring cytokine secretion.
Elsässer-Beile U; Wetterauer U; Schultze-Seemann W; Gallati H; Mönting JS; von Kleist S
Cancer Immunol Immunother; 1996 Feb; 42(2):93-8. PubMed ID: 8620526
[TBL] [Abstract][Full Text] [Related]
4. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours.
Schöndorf T; Engel H; Lindemann C; Kolhagen H; von Rücker AA; Mallmann P
Cancer Immunol Immunother; 1997 Apr; 44(2):88-96. PubMed ID: 9177470
[TBL] [Abstract][Full Text] [Related]
5. Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.
Radrizzani M; Gambacorti-Passerini C; Parmiani G; Fossati G
Cancer Immunol Immunother; 1989; 28(1):67-73. PubMed ID: 2462469
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.
Dadmarz R; Sgagias MK; Rosenberg SA; Schwartzentruber DJ
Cancer Immunol Immunother; 1995 Jan; 40(1):1-9. PubMed ID: 7828162
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma.
Bateman WJ; Donnellan I; Fraser IA; Wong LS; Morris AG
Cancer Immunol Immunother; 1995 Jul; 41(1):61-7. PubMed ID: 7641220
[TBL] [Abstract][Full Text] [Related]
8. Evidence for immune defects in breast and lung cancer patients.
Caras I; Grigorescu A; Stavaru C; Radu DL; Mogos I; Szegli G; Salageanu A
Cancer Immunol Immunother; 2004 Dec; 53(12):1146-52. PubMed ID: 15185014
[TBL] [Abstract][Full Text] [Related]
9. Native and inducible levels of natural cytotoxicity in lymph nodes draining mammary carcinoma.
Kimber I; Moore M; Howell A; Wilkinson MJ
Cancer Immunol Immunother; 1983; 15(1):32-8. PubMed ID: 6553505
[TBL] [Abstract][Full Text] [Related]
10. Dual Functions of T Lymphocytes in Breast Carcinoma: From Immune Protection to Orchestrating Tumor Progression and Metastasis.
Zareinejad M; Mehdipour F; Roshan-Zamir M; Faghih Z; Ghaderi A
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835465
[TBL] [Abstract][Full Text] [Related]
11. Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood.
Wall I; Boulat V; Shah A; Blenman KRM; Wu Y; Alberts E; Calado DP; Salgado R; Grigoriadis A
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139665
[TBL] [Abstract][Full Text] [Related]
12. Immune System Effects on Breast Cancer.
Amens JN; Bahçecioglu G; Zorlutuna P
Cell Mol Bioeng; 2021 Aug; 14(4):279-292. PubMed ID: 34295441
[TBL] [Abstract][Full Text] [Related]
13. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.
Garaud S; Buisseret L; Solinas C; Gu-Trantien C; de Wind A; Van den Eynden G; Naveaux C; Lodewyckx JN; Boisson A; Duvillier H; Craciun L; Ameye L; Veys I; Paesmans M; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
JCI Insight; 2019 Aug; 5(18):. PubMed ID: 31408436
[TBL] [Abstract][Full Text] [Related]
14. Correlation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric study.
Kim JH; Chon SK; Im KS; Kim NH; Sur JH
Can J Vet Res; 2013 Apr; 77(2):142-9. PubMed ID: 24082407
[TBL] [Abstract][Full Text] [Related]
15. Low serum creatine kinase levels in breast cancer patients: a case-control study.
Pan H; Xia K; Zhou W; Xue J; Liang X; Cheng L; Wu N; Liang M; Wu D; Ling L; Ding Q; Chen L; Zha X; Liu X; Wang S
PLoS One; 2013; 8(4):e62112. PubMed ID: 23614022
[TBL] [Abstract][Full Text] [Related]
16. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?
Golubnitschaja O; Yeghiazaryan K; Costigliola V; Trog D; Braun M; Debald M; Kuhn W; Schild HH
EPMA J; 2013 Feb; 4(1):6. PubMed ID: 23418957
[TBL] [Abstract][Full Text] [Related]
17. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
[TBL] [Abstract][Full Text] [Related]
18. Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients.
Llanes-Fernández L; Arango-Prado Mdel C; Alcocer-González JM; Guerra-Yi ME; Franco-Odio S; Camacho-Rodríguez R; Madrid-Marina V; Tamez-Guerra R; Rodríguez-Padilla C
J Cancer Res Clin Oncol; 2009 Feb; 135(2):255-64. PubMed ID: 18651178
[TBL] [Abstract][Full Text] [Related]
19. Intracellular esterase activity in living cells may distinguish between metastatic and tumor-free lymph nodes.
Afrimzon E; Deutsch A; Shafran Y; Zurgil N; Sandbank J; Pappo I; Deutsch M
Clin Exp Metastasis; 2008; 25(3):213-24. PubMed ID: 18197360
[TBL] [Abstract][Full Text] [Related]
20. PTGS2 (COX-2) -765 G > C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma.
Ben Nasr H; Chahed K; Bouaouina N; Chouchane L
Mol Biol Rep; 2009 Jan; 36(1):193-200. PubMed ID: 17968676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
